HC Wainwright Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA)

Research analysts at HC Wainwright started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 165.71% from the company’s current price.

A number of other research analysts have also recently commented on the company. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Guggenheim boosted their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and an average target price of $23.14.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $9.79 on Wednesday. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $535.04 million, a price-to-earnings ratio of -5.15 and a beta of 1.97. The firm’s fifty day simple moving average is $8.57 and its 200 day simple moving average is $8.09. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $10.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the previous year, the business posted ($0.40) EPS. As a group, equities research analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares in the last quarter. Invesco Ltd. raised its holdings in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after acquiring an additional 3,007 shares in the last quarter. Corebridge Financial Inc. raised its holdings in Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after acquiring an additional 3,801 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock valued at $1,148,000 after acquiring an additional 3,827 shares in the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after acquiring an additional 4,384 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.